Induced pluripotent stem (iPS) cells present a seminal discovery in cell biology and promise to support innovative treatments of so far incurable diseases. To translate iPS technology into clinical trials, the safety and stability of these reprogrammed cells needs to be shown. In recent years, different non-viral transposon systems have been developed for the induction of cellular pluripotency, and for the directed differentiation into desired cell types. In this review, we summarize the current state of the art of different transposon systems in iPS-based cell therapies.

中文翻译：

---

转座子介导的细胞重编程向基于细胞的疗法的潜力。

诱导多能干（iPS）细胞是细胞生物学的开创性发现，并有望支持迄今无法治愈的疾病的创新治疗。要将iPS技术转化为临床试验，需要显示这些重新编程的细胞的安全性和稳定性。近年来，已开发出不同的非病毒转座子系统来诱导细胞多能性，并定向分化成所需的细胞类型。在这篇综述中，我们总结了基于iPS的细胞治疗中不同转座子系统的最新技术水平。